Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Non-Current Liabilities (2020 - 2022)

Caribou Biosciences (CRBU) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $73.5 million as the latest value for Q2 2022.

  • On a quarterly basis, Total Non-Current Liabilities rose 31.74% to $73.5 million in Q2 2022 year-over-year; TTM through Jun 2022 was $73.5 million, a 31.74% increase, with the full-year FY2021 number at $54.5 million, up 203.12% from a year prior.
  • Total Non-Current Liabilities was $73.5 million for Q2 2022 at Caribou Biosciences, down from $74.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $74.2 million in Q1 2022 to a low of $18.0 million in Q4 2020.
  • A 3-year average of $55.6 million and a median of $56.6 million in 2021 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 203.12% in 2021, then skyrocketed 31.74% in 2022.
  • Caribou Biosciences' Total Non-Current Liabilities stood at $18.0 million in 2020, then skyrocketed by 203.12% to $54.5 million in 2021, then skyrocketed by 34.79% to $73.5 million in 2022.
  • Per Business Quant, the three most recent readings for CRBU's Total Non-Current Liabilities are $73.5 million (Q2 2022), $74.2 million (Q1 2022), and $54.5 million (Q4 2021).